-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-338 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Marginal Zone B-cell Lymphoma Drug Details: LOXO-338 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-338 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Multiple Myeloma (Kahler Disease) Drug Details: LOXO-338 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-338 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in Mantle Cell Lymphoma Drug Details: LOXO-338 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LOXO-338 in B-Cell Chronic Lymphocytic Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LOXO-338 in B-Cell Chronic Lymphocytic Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LOXO-338 in B-Cell Chronic Lymphocytic Leukemia Drug Details: LOXO-338 is...
-
Product Insights
NewNeuroendocrine Tumors – Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Tumors – Drugs In Development, 2024 report and make more profitable business decisions. Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and...
-
Product Insights
NewPapillary Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Papillary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes...
-
Product Insights
NewFollicular Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Follicular Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer,...
-
Product Insights
NewB-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack...
-
Product Insights
NewWaldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Waldenstrom macroglobulinemia, one of the malignant monoclonal gammopathies, is a chronic, indolent, lymphoproliferative disorder. It is characterized by the presence of a high level of a macroglobulin (immunoglobulin M [IgM]), elevated serum viscosity, and the presence of a lymphoplasmacytic infiltrate in the bone marrow. Waldenström macroglobulinemia is considered to be a lymphoplasmacytic lymphoma, as defined by the Revised European American...
-
Product Insights
NewB-Cell Leukemia – Drugs In Development, 2024
Empower your strategies with our B-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell leukemia is a type of blood cancer that originates in the bone marrow, affecting B lymphocytes (B cells), a crucial component of the immune system. This leukemia results in the uncontrolled growth and accumulation of abnormal B cells, which hinder the normal production of healthy blood cells. Diagnosis involves blood tests, bone marrow biopsies, and imaging scans to identify and classify...